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Abstract
Background and objectives
Cardiovascular and respiratory diseases can frequently coexist. Understanding their link
may improve disease management. We aimed at assessing the associations of chronic
bronchitis (CB), asthma and rhinitis with cardiovascular diseases and risk factors in the gen-
eral population.
Methods
We used data collected in the Gene Environment Interactions in Respiratory Diseases
study, an Italian multicentre, multicase-control study. Among 2463 participants (age 21–86,
female 50%) who underwent standardized interviews, skin prick and lung function tests, we
identified 254 cases of CB without airflow obstruction, 418 cases of asthma without CB, 959
cases of rhinitis alone, and 832 controls. The associations of respiratory diseases with
reported cardiovascular risk factors (lifestyles, hypertension, dyslipidaemia), heart disorders
(myocardial infarction, coronary thrombosis, angina, aorta or heart surgery) and intermittent
claudication were estimated through relative risk ratios (RRR) by multinomial logistic regres-
sion models.
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Results
Compared to controls, CB cases were more likely to be heavy smokers, alcohol consumers,
physically inactive, and to suffer from hypertension or dyslipidaemia; rhinitis cases were
less obese but more likely to have hypertension. Asthma was significantly associated with
current smoking. After adjusting for cardiovascular risk factors, heart disorders were associ-
ated with CB (RRR[95%CI]: 1.58[1.12–2.22]) and rhinitis (1.35[0.98–1.85]) and intermittent
claudication was associated with CB (3.43[2.52–4.67]), asthma (1.51[1.04–2.21]) and rhini-
tis (2.03[1.34–3.07]).
Conclusions
CB, asthma and rhinitis were associated with cardiovascular risk factors and diseases. In
particular, CB shared with cardiovascular diseases almost all risk factors and was strongly
associated with a higher risk of heart disorders and intermittent claudication.
Introduction
Several previous studies have shown a significantly increased risk of cardiovascular diseases in
COPD and clinicians have long recognized that cardiovascular diseases are the major contrib-
utor to morbidity and mortality in patients with COPD [1,2].
Other respiratory diseases have been associated with cardiovascular diseases. Large popula-
tion studies showed that patients with chronic bronchitis (CB), a respiratory condition associ-
ated with a decline in lung function [3], have increased respiratory, cardiovascular and all-
cause mortality [4–7].
Data on the association between asthma and cardiovascular diseases are conflicting [8–14],
and few studies have addressed the relationship between rhinitis and cardiovascular diseases
[15–17].
Previous research on the intriguing coexistence of respiratory and cardiovascular diseases
generally focused on a single respiratory disorder, and few studies investigated the cardiovas-
cular risk factors associated with airway illnesses. With this in mind, we aimed to investigate
the association of cardiovascular diseases and cardiovascular risk factors with CB, asthma and
rhinitis, by analysing data collected in the population-based Gene Environment Interactions
in Respiratory Diseases (GEIRD) study.
Methods
Study design and selection of the cohort
GEIRD is a two-stage multicentre, multicase–control study carried out in Italy (www.geird.
org) [18]. In the first stage, new random samples of adults (GEIRD 20–64 years) and elderly
subjects (GEIRD 65–85 years), male/female = 1/1, or pre-existing randomly sampled cohorts
from the general population (ISAYA, ECRHS Italy and ECRHS III) were surveyed for respira-
tory symptoms between 2006 and 2010 using a postal questionnaire, as reported in Table 1
and described elsewhere [19]. Overall, 14,513 subjects from the centres of Verona, Pavia,
Torino, Ancona, Sassari answered the questionnaire (response rate: 59%). All the subjects who
reported symptoms suggestive of asthma or chronic bronchitis, a random sample (30%) of the
subjects who reported rhinitis or hay fever and a random sample (40%) of the subjects who did
not report respiratory symptoms, diagnoses or hospitalizations were invited to clinics. Addi-
tionally, a sample of 439 subjects from Palermo was invited. Overall, 7,025 subjects were
Respiratory health and cardiovascular risk factors
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invited to GEIRD stage-2 [20]. Between 2007 and 2015, the participants in GEIRD stage-2
were 2,911 subjects (participation rate: 41%). In all centres, clinical examinations were carried
out following standardised protocols. Ethical approval was obtained from the following ethics
committees: Verona, Comitato Etico per la Sperimentazione dell’Azienda Ospedaliera Istituti
Ospitalieri di Verona; Turin, Comitato Etico dell’Azienda Sanitaria Locale TO/2 di Torino;
Pavia, Comitato di Bioetica della Fondazione IRCCS Policlinico San Matteo di Pavia; Ancona,
Comitato Etico dell’Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona; Sassari,
Comitato di Bioetica dell’Azienda Sanitaria Locale di Sassari; Palermo, Comitato Etico dell’A-
zienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello. Written consent was obtained from
each participant.
Clinical measurements
Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured
according to the American Thoracic Society reproducibility criteria [21]. Lung function values
were expressed as a percentage of predicted values, and the lower limit of normal LLN for the
FEV1/FVC was calculated according to Quanjer [22]. Spirometry was performed again 10 min
after the administration of 400 μg salbutamol in subjects with FEV1/FVC <70% or <LLN. The
subjects with FEV1/FVC�70% and�LLN underwent the methacholine challenge, according
to a standardized protocol [23]. A subject’s test was positive if FEV1 decreased by 20% at a
maximum cumulative dose�1 mg methacholine (PD20�1).
The subjects were skin tested for a panel of 14 aeroallergens [20]. A subject was considered
to be atopic if positive to one or more of the tested allergens.
Identification of cases and controls in clinics
Based on the symptoms reported and the results of the clinical tests, 2,463 subjects were hierar-
chical classified into four groups: CB (n = 254), asthma (n = 418), rhinitis (n = 959), and con-
trols (n = 832). The cases and control groups were defined as follows:
Table 1. Study population by centre and cohort.
Center Cohort Invited to stage 2 Participating in stage 2 Included in the analysis Females (%) Age, years
(mean ± SD)
Verona ECRHS III 185 98 95 47.4 54.2 ± 7.6
GEIRD 20–64 2,961 1,329 1,165 52.2 44.5 ± 10.2
ISAYA
ECRHS Italy
GEIRD 65–84 591 132 97 34.0 71.8 ± 2.8
Turin ECRHS III 178 76 69 55.1 53.9 ± 6.3
GEIRD 20–64 589 359 282 52.1 46.8 ± 10.3
Pavia ECRHS III 186 95 86 53.5 57.2 ± 6.7
GEIRD 20–64 489 241 204 62.3 50.9 ± 11.0
Ancona GEIRD 20–44 575 99 91 53.8 42.3 ± 5.3
Sassari GEIRD 65–84 439 189 122 32.0 74.2 ± 4.3
ISAYA 393 230 207 49.3 45.0 ± 6.9
Palermo GEIRD 65–84 439 63 45 33.3 75.1 ± 4.7
Overall 7,025 2,911 2,463 50.7 49.5 ± 12.8
ECRHS, European Community Respiratory Health Survey; GEIRD, Gene Environment Interactions in Respiratory Diseases; ISAYA, Italian Study on Asthma in Young
Adults.
https://doi.org/10.1371/journal.pone.0224999.t001
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• cases of chronic bronchitis (CB): subjects with self-reported cough and phlegm for the most
of days in 3 consecutive months, during 2 years, with post-bronchodilator FEV1/FVC�70%
and�LLN.
• cases of asthma: subjects without CB who had 1) self-reported asthma, plus one among 1.1)
having had an asthma attack in the last 12 months, 1.2) current use of medications for
asthma; or 2) asthma-like symptoms or use of medicines for breathing problems in the last
12 months, plus one among 2.1) PD20�1 mg, 2.2) pre-bronchodilator FEV1/FVC <70% or
<LLN with a positive reversibility test (i.e. FEV1 improvement� 12% and� 200mL after
400μg of salbutamol);
• cases of rhinitis: subjects without CB and asthma who had one among 1) lifetime nasal aller-
gies, including ‘hay fever’; 2) lifetime problem with sneezing, or a runny or a blocked nose
(without cold/flu); 3) recurrent nasal/eye symptoms in the presence of dust, pollens or
animals.
• controls: subjects who were not cases and had both (i) pre-bronchodilator FEV1/FVC�70%
and�LLN; and (ii) FEV1> 80% predicted.
Sixty-eight subjects with COPD, defined as having both persistent respiratory symptoms
(dyspnoea, cough, and/or sputum production) and airflow limitation (post-bronchodilator
FEV1/FVC<70% or <LLN), and 380 subjects who did not correspond to any of the defini-
tions above or with missing values on key information were excluded from the analyses.
Cardiovascular diseases
Two different self-reported doctor-diagnosed cardiovascular conditions were considered [24]:
1. heart disorders, defined as having any among coronary heart disease (‘Did a physician tell
you that you suffer from: myocardial infarction, coronary thrombosis, or angina?’), heart/
aortic surgery (‘Have you ever undergone heart or aortic surgery?’).
2. intermittent claudication. A subject was considered to have intermittent claudication if
he/she answered yes to the question: ‘Do you get a pain or discomfort in your legs when
you walk?’, plus he/she reported that it usually disappeared in 10 min or less when standing
still [25]. Intermittent claudication was adopted as proxy of peripheral arterial disease [26].
Covariates
Information on the following variables was collected during the clinical interview and was
taken into account for the analyses: age, gender, school education as a proxy of the socio-eco-
nomic status (low if had completed full-time education before the age of 16), smoking habits
(lifetime non-smoker, ex-smoker, current smoker), daily alcohol intake (lifetime non-con-
sumer, moderate (�15 g/day), high (>15 g/day)), sedentary life (usually doing physical exer-
cise less than once per month), and self-reported diabetes, hypertension or dyslipidaemia
(high levels of cholesterol or triglycerides).
Statistical analysis
The subjects’ characteristics were summarized as percentages or means (SD). The Pearson’s
chi-squared test, Fisher’s exact test and ANOVA were used to test differences across cases and
controls (α = 0.05). The associations of cardiovascular diseases/risk factors with respiratory
diseases were estimated through relative risk ratios (RRR) obtained by multinomial logistic
Respiratory health and cardiovascular risk factors
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regression models using the case/control indicator (0 = control, 1 = chronic bronchitis,
2 = asthma, 3 = rhinitis) as the dependent variable and cardiovascular diseases/risk factors as
the main independent variable. Three models were fitted to the data: (i) adjusted for age and
sex; (ii) further adjusted for smoking habits, alcohol consumption, body mass index (BMI, in
categories <25, 25–30 and>30 kg/m2), school education and physical activity; (iii) further
adjusted for the comorbidity indicators (diabetes, hypertension, dyslipidaemia). Centre was
considered a clustering factor and cluster-robust standard errors were used.
Statistical analyses were performed with STATA 13.1 (Stata Corp. College Station, TX,
USA).
Results
Overall, 2,463 subjects were classified as cases or controls and included in the study. The age
ranged from 21 to 86 years, and 50.7% (n = 1,249) were females (Table 1).
As a result of our hierarchical definitions, cases of CB could also be affected by asthma
(n = 115, 45.3%) as well as rhinitis (n = 205, 80.7%), and cases of asthma could also be affected
by rhinitis (n = 354, 84.7%). Cases of asthma and CB had a significantly lower FEV1 and FEV1/
FVC ratio than controls (Table 2). The proportion of subjects with atopy was significantly
higher among cases of CB, asthma and rhinitis (57.8, 79.0 and 62.5%, respectively) compared
to the control group (26.0%).
Table 2. Distribution of risk factors, clinical characteristics and lung function measurements by cases-control status.
Chronic bronchitis Asthma Rhinitis Controls p-value
n = 254 n = 418 n = 959 n = 832
Sex (females) 145 (57.1) 194 (46.4) 496 (51.7) 414 (49.8) 0.048
Age (year) 48.4 ± 12.8 46.4 ± 12.2 49.7 ± 13.0 51.1 ± 12.6 <0.001
Low education 65 (25.7) 64 (15.6) 152 (16.0) 161 (19.5) 0.001
Smoking habits <0.001
never smokers 112 (44.1) 196 (46.9) 490 (51.3) 430 (54.7)
ex-smokers 58 (22.8) 125 (29.9) 295 (30.9) 268 (32.3)
current-smokers 84 (33.1) 97 (23.2) 171 (17.9) 133 (16.0)
Alcohol consumption 0.005
no 133 (53.4) 231 (56.6) 594 (63.0) 543 (62.9)
moderate (�15 g/day) 66 (26.5) 115 (28.2) 222 (23.5) 210 (25.7)
high (>15 g/day) 50 (20.1) 62 (15.2) 127 (13.5) 93 (11.4)
Sedentary life 163 (64.2) 212 (50.8) 488 (51.2) 437 (52.5) 0.002
BMI 0.388
<25 kg/m2 123 (50.6) 224 (54.9) 511 (55.8) 317 (50.2)
25–30 kg/m2 82 (33.7) 127 (31.1) 295 (32.2) 292 (35.1)
>30 kg/m2 38 (14.7) 57 (14.0) 110 (12.0) 122 (14.7)
Diabetes 9 (3.5) 11 (2.6) 35 (3.7) 31 (3.7) 0.766
Hypertension 80 (31.6) 91 (21.8) 243 (25.4) 199 (24.0) 0.032
Dyslipidaemia 97 (38.2) 115 (27.7) 277 (29.0) 254 (30.5) 0.022
FEV1 (L) 3.15 ± 0.87 3.24 ± 0.89 3.29 ± 0.83 3.32 ± 0.78 <0.001
FVC (L) 4.02 ± 1.09 4.20 ± 1.15 4.05 ± 1.03 4.04 ± 0.96 <0.001
FEV1/FVC ratio (%) 78.6 ± 8.6 77.4 ± 6.8 81.3 ± 6.3 82.4 ± 6.0 <0.001
FEV1 (% of predicted) 96.2 ± 14.7 94.4 ± 14.0 100.9 ± 12.9 103.2 ± 12.3 <0.001
Atopy 122 (57.8) 278 (79.0) 498 (62.5) 177 (26.0) <0.001
Data are presented as n (%) or mean ± standard deviation.
https://doi.org/10.1371/journal.pone.0224999.t002
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The groups differed in the distribution of sex and age, as well as of most of lifestyle variables
and cardiovascular risk factors: education, smoking habits, alcohol consumption, physical
activity, hypertension, dyslipidaemia (Table 2). In particular, CB was significantly associated
with female sex (RRR 1.63, 95%CI: 1.31–2.04), younger age (0.96, 0.94–0.98), and low educa-
tion (1.78; 1.24–2.54) (Table 3).
Current smoking (2.00, 1.41–2.84), high alcohol consumption (2.55, 1.61–4.03) and seden-
tary life (1.59, 1.05–2.42) were also associated with an increased risk of CB. The risk of having
asthma was higher in younger subjects (0.96, 0.95–0.98) and in current smokers (1.52, 1.20–
1.94). The risk of having rhinitis was lower in overweight subjects (0.86, 0.79–0.94). Hyperten-
sion was significantly associated with CB (1.90, 1.14–3.15), asthma (1.41, 1.06–1.89) and rhini-
tis (1.42, 1.13–1.77). Dyslipidaemia was associated with CB (1.66, 1.19–2.31).
The crude prevalence of heart disorders was higher among cases of CB and rhinitis (14.2%
and 12.1%) compared to controls and asthma cases (10.1% and 9.3%) (Fig 1).
After adjustment for all cardiovascular risk factors and comorbidities (Fig 2, model 3),
heart disorders were significantly associated with CB (RRR, 95%CI: 1.58, 1.12–2.22; p = 0.009).
A borderline association was also detected between heart disorders and rhinitis (RRR, 95%CI:
1.35, 0.98–1.85; p = 0.066).
The prevalence of intermittent claudication was higher in all the cases groups (10.6%, 4.8%,
6.0% in CB, asthma, and rhinitis groups, respectively) than in controls (3.3%) (Fig 1). In the
fully adjusted model (Fig 2, model 3), intermittent claudication was significantly associated
with a 3.5-fold higher risk of CB (RRR 3.43, 95%CI: 2.52–4.67; p<0.001), a 2-fold higher risk
of rhinitis (2.03, 1.34–3.07; p<0.001), and a 1.5-fold higher risk of asthma (1.51, 1.04-2-21;
p = 0.032).The associations were confirmed when using different sets of adjustment variables
(Fig 2, models 1 and 2).
Table 3. Relative risk ratios, with 95% confidence intervals, for the associations of demographics, cardiovascular risk factors and comorbidities with CB, asthma,
and rhinitis.
Chronic bronchitis
vs. Controls
RRR (95% CI)
Asthma
vs. Controls
RRR (95% CI)
Rhinitis
vs. Controls
RRR (95% CI)
Sex (female vs. male) 1.63 (1.31–2.04) 0.91 (0.76–1.10) 1.09 (0.96–1.24)
Age (per year increase) 0.96 (0.94–0.98) 0.96 (0.95–0.98) 0.99 (0.98–1.00)
Education (low vs. high) 1.78 (1.24–2.54) 1.00 (0.66–1.50) 0.82 (0.66–1.02)
Smoking habits
ex vs. never smokers 0.78 (0.59–1.03) 1.15 (0.91–1.46) 1.01 (0.84–1.22)
current vs. never smokers 2.00 (1.41–2.84) 1.52 (1.20–1.94) 1.16 (0.98–1.37)
Alcohol consumption
moderate vs. no 1.27 (0.87–1.86) 0.98 (0.74–1.28) 0.90 (0.70–1.16)
high vs. no 2.55 (1.61–4.03) 1.44 (0.99–2.11) 1.22 (0.92–1.61)
Sedentary vs. active life 1.59 (1.05–2.42) 1.02 (0.83–1.26) 0.96 (0.73–1.26)
BMI
25–30 vs. <25 kg/m2 1.00 (0.78–1.30) 0.91 (0.66–1.27) 0.86 (0.79–0.94)
>30 vs <25 kg/m2 0.88 (0.64–1.21) 0.99 (0.75–1.30) 0.73 (0.52–1.03)
Diabetes (yes vs.no) 0.91 (0.50–1.67) 0.82 (0.38–1.79) 1.12 (0.78–1.61)
Hypertension (yes vs.no) 1.90 (1.14–3.15) 1.41 (1.06–1.89) 1.42 (1.13–1.77)
Dyslipidaemia (yes vs.no) 1.66 (1.19–2.31) 1.02 (0.84–1.24) 0.95 (0.83–1.09)
Adjusted for all the variables included in the table. RRR, relative risk ratio
https://doi.org/10.1371/journal.pone.0224999.t003
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Discussion
In the present analysis of data from the general population, we found that heart disorders and
intermittent claudication, an indicator of symptomatic peripheral artery disease, were both
strongly associated with CB and, to a minor extent, with rhinitis; intermittent claudication was
also associated with asthma. Our data also indicate that cardiovascular risk factors are fre-
quently associated with respiratory illnesses. Particularly, our findings support that unhealthy
lifestyles (smoking, high alcohol consumption and sedentariness), hypertension and dyslipi-
daemia may predict a greater risk of CB.
Our findings should be interpreted keeping in mind that, in this multicase-control study,
we used a hierarchical classification of diseases, so that cases of chronic bronchitis may also
suffer from asthma and rhinitis, and cases of asthma could also be affected by rhinitis. Further-
more we underline that control subjects were accurately selected on the basis of the absence of
CB, asthma and rhinitis.
CB was strongly and independently associated with heart disorders. Of note, as cases of
COPD were excluded from the analysis, all subjects reporting CB presented a preserved lung
function. Our results are in agreement with previous studies, demonstrating an increased risk
of coronary disease and mortality among subjects with symptoms of CB [4,27,28]. In the above
mentioned studies, lung function test was not performed, so that CB population could include
subjects with COPD, which is known to be associated with cardiovascular diseases [2]. Lange
et al. [5] and Guerra et al.[3] demonstrated an association between CB without bronchial
obstruction, and all-cause death, indirectly supporting the results from the present analysis.
Fig 1. Prevalence of heart disorders and intermittent claudication in subjects with CB, asthma, rhinitis, and controls.
https://doi.org/10.1371/journal.pone.0224999.g001
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PLOS ONE | https://doi.org/10.1371/journal.pone.0224999 November 7, 2019 7 / 13
This study is the first to report an association between CB and intermittent claudication,
which remained significant after controlling for all the most important cardiovascular risk fac-
tors. These results suggest that CB may be an independent risk factor for atherosclerosis.
The lack of a significant association between asthma and heart disorders is in agreement
with Schanen and colleagues, who reported that asthma is not a risk factor for coronary heart
disease [10]. Nonetheless, some reports suggested an association of asthma with carotid ath-
erosclerosis, coronary heart disease and stroke [9–14]. One possible explanation for the con-
trasting results is the fact that, differently from previous studies [9–12], we analysed asthma
separately from CB, a disorder we found strongly associated with cardiovascular risk factors
and diseases. Furthermore, in our study asthma was precisely characterized, whereas it was
self-reported in some previous investigations [13], a fact that could introduce a bias of misclas-
sification with COPD [29].
Extending the finding of our previous analysis that was carried out using data from the cen-
tre of Verona alone [16], subjects with rhinitis and/or asthma had an increased risk of suffering
from intermittent claudication.
Few studies investigated the relationship between cardiovascular diseases and rhinitis
[17,30]. In disagreement with our results, Hirsch et al. did not find a significant association
between chronic rhino-sinusitis and post-morbid cardiovascular conditions [31].
The strong association of smoking with CB is not surprising [32], but we also found an
increased risk of asthma among current smokers, in line with findings from others [33,34].
Our results do not support previous findings suggesting a relationship between smoking
and prevalence of chronic rhinitis [35].
Fig 2. Relative risk ratios (RRR) with 95% CIs for the associations of CB, asthma, and rhinitis with heart disorders and intermittent claudication. Model 1 (white
triangles): adjusted for age and gender; model 2 (grey triangles): adjusted for age, gender, school education, smoking status, alcohol consumption, BMI, physical activity;
model 3 (black triangles): adjusted for variables in model 2 plus diabetes, hypertension, dyslipidaemia.
https://doi.org/10.1371/journal.pone.0224999.g002
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We found an association between dyslipidaemia and CB. Subjects with CB are more likely
to be heavy smokers and alcohol consumers, which may be responsible of an altered lipid
metabolism [36,37]. However, the association between dyslipidaemia and CB persisted after
controlling for these confounders.
Another interesting result is that subjects with rhinitis were less likely to be overweight or
obese, which was also observed in other two recent surveys [38,39].
Differently from previous studies showing an association between obesity and the risk of
asthma [40], we found no relationship between asthma and BMI.
In agreement with previous studies [41], elevate alcohol consumption was independently
correlated with CB. Alcohol acts systemically with various mechanisms (alteration of immu-
nity and promotion of systemic inflammation) [42], that may be involved in both the respira-
tory and cardiovascular damage.
Our finding of a relationship between rhinitis and hypertension is consistent with a previ-
ous study by Kony et al. [43]. Our data also indirectly support another case-control study that
suggested an increased incidence of hypertension among subjects with rhino-sinusitis [31].
While the association between COPD and hypertension has widely been described [2], our
study is the first to report a strong positive association between CB and this risk factor. Our
data also show the increased risk of arterial hypertension among asthmatic subjects, in agree-
ment with previous findings from large population based studies [9,44].
The nature of the association of cardiovascular disorders with rhinitis and CB remains spec-
ulative and several mechanisms, such as infection [45–47] and inflammation, may play a role.
The association of atherosclerosis with respiratory diseases could also be caused by the inher-
ent susceptibility of some subjects to specific inflammatory pathways. There is evidence that
patients with rhino-sinusitis [48] and CB [3] have higher levels of C-reactive protein, a predic-
tive marker of coronary heart disease [49].
Asthma and CB are both characterized by chronic inflammation in the lung, even though
the nature of the inflammation differs between the two disorders [8,50]. The different types of
inflammation probably result in distinct pathology, clinical manifestation [8], and could differ-
ently influence the development of cardiovascular comorbidities.
Finally, reversal causation could not be excluded, since our study design does not consent
to assess the temporal relationship between respiratory disorders, cardiovascular diseases and
risk factors. Subjects affected by cardiovascular disease and hypertension often use medication
that might induce respiratory symptoms (such as cough) or disorders (such as rhinitis) [51].
However the association between rhinitis, CB, asthma and hypertension was not modified
after adjusting for antihypertensive treatment (data not shown).
The strength of our analysis is based on the standardized protocol which allowed a precise
definition of each respiratory disease. A limit is that cardiovascular events were self-reported.
However, a previous study from the general population showed a good sensitivity and specific-
ity for self-reported diagnosis of cardiovascular events [24].
We conclude that a better understanding of the relationship between respiratory and car-
diovascular diseases could have important clinical implications. First of all, CB, which is often
considered as a minor symptom, has to be viewed as a status possibly evolving not only to irre-
versible airway obstruction [3] but also to cardiovascular damage. Secondly, there are possible
consequences for disease management, such as screening, prevention and early treatment of
cardiovascular diseases and risk factors in patients with chronic bronchitis, even in absence of
irreversible airflow obstruction. In turn, in patients with cardiovascular diseases caution
should be adopted about the use of drugs that could negatively interfere with the respiratory
system (e.g. angiotensin-converting enzyme inhibitors potentially inducing cough).
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In our study, cases of CB may also suffer from asthma and rhinitis. Thus our data suggest
the crucial weight of cough and phlegm in driving the association between respiratory and car-
diovascular risk factors and diseases. As a matter of fact, the strength of the associations was
lower among subjects with asthma or rhinitis who did not complain of CB. This attention to
CB may have also a strong preventive consequence, since the disease is generally present even
without a clinically significant airway derangement. A similar consideration is also of impor-
tance for rhinitis, taking into account its association with peripheral arterial disease.
Finally, although the design of our study does not allow definitive conclusions, we are
tempted to speculate that some cardiovascular risk factors, such as sedentariness, hypertension
and dyslipidaemia, might also be involved in the development of respiratory diseases.
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